Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 3, 2010, Pages 247-253

  Maryanoff, Bruce E ^a   De Garavilla, Lawrence ^a   Greco, Michael N ^a   Haertlein, Barbara J ^a   Wells, Grace I ^a   Andrade Gordon, Patricia ^a   Abraham, William M ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Asthma; Enzyme inhibitor; Mast cells; Neutrophils; Pulmonary disease; Serine protease; Tobacco smoke

Indexed keywords

ANTIINFLAMMATORY AGENT; CATHEPSIN G; CHYMASE; DEXAMETHASONE; OVALBUMIN; RWJ 355871; SERINE PROTEINASE INHIBITOR; TOBACCO SMOKE; UNCLASSIFIED DRUG;

AIRWAY DYNAMICS; ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; INFLAMMATION; MAST CELL; MOUSE; NEUTROPHILIA; NONHUMAN; PATHOPHYSIOLOGY; PAW EDEMA; PRIORITY JOURNAL; RAT; SHEEP;

ANIMALS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CATHEPSIN G; CHYMASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INJECTIONS, INTRAVENOUS; LUNG DISEASES; MICE; PHOSPHONIC ACIDS; PIPERIDINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; SHEEP; TREATMENT OUTCOME;

EID: 76749104410     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200904-0627OC     Document Type: Article

References (52)

1. Woodruff PG, Fahy JV. Asthma: prevalence, pathogenesis, and prospects for novel therapies. JAMA 2001;286:395-398.
2. Faulkner MA, Hilleman DE. Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future. Pharmacotherapy 2003;23:1300-1315.
3. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003;54:113-129.
4. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312.
5. Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol 1999;104:S132-S137.
6. Holgate ST. The role of mast cells and basophils in inflammation. Clin Exp Allergy 2000;1:28-32.
7. Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002;1: 437-446.
8. Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans 2002;30:98-102.
9. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999;160:S49-S52.
10. Molinari JF, Scuri M, Moore WR, Clark J, Tanaka R, Abraham WM. Inhaled tryptase causes bronchoconstriction in sheep via histamine release. Am J Respir Crit Care Med 1996;154:649-653.
11. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 1999;65:137-150.
12. Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol 2001;69:197-206.
13. Hart PH. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 2001;79:149-153.
14. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007;217:141-154.
15. de Garavilla L, Greco MN, Sukumar N, Chen Z-W, Pineda AO, Mathews FS, Di Cera E, Giardino EC, Wells GI, Haertlein BJ, et al. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem 2005;280:18001-18007.
16. Owen CA, Campbell EJ. Neutrophil proteinases and matrix degradation: the cell biology of pericellular proteolysis. Semin Cell Biol 1995; 6:367-376.
17. Miller HR, Pemberton AD. Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut. Immunology 2002;105:375-390.
18. Schechter NM, Pereira PJB, Strobl S. Structure and function of human chymase. In: Marone G, Lichtenstein LM, Galli SJ, editors. Mast cells and basophils. London: Academic Press; 2000. Pp. 275-290.
19. Feitosa RF, Melciades GB, Assreuy AM, Rocha MF, Ribeiro RA, Lima AA. The pharmacological profile of ovalbumin-induced paw oedema in rats. Mediators Inflamm 2002;11:155-163.
20. Abraham WM. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 2008;21:743-754.
21. Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS. p38α-Selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model to tobacco smoke-induced airway in-flammation. J Pharmacol Exp Ther 2008;324:921-929.
22. Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, Corcoran TW, de Garavilla L, Kauffman JA, Recacha R, Chattopadhyay D, Andrade-Gordon P, et al. Nonpeptide inhibitors of cathepsin G: optimization of a novel beta-ketophosphonic acid lead by structure-based drug design. J Am Chem Soc 2002;124:3810-3811.
23. Abraham WM, Ahmed A, Serebriakov I, Carmillo AN, Ferrant J, de Fougerolles AR, Garber EA, Gotwals PJ, Koteliansky VE, Taylor F, et al. A monoclonal antibody to α1β1 blocks antigen-induced airway responses in sheep. Am J Respir Crit Care Med 2004;169:97-104.
24. Kasaian MT, Donaldson DD, Tchistiakova L, Marquette K, Tan XY, Ahmed A, Jacobson BA, Widom A, Cook TA, Xu X, et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol 2007;36:368-376.
25. Rosen SD, Tsay D, Singer MS, Hemmerich S, Abraham WM. Therapeutic targeting of endothelial ligands for L-selectin (PNAd) in a sheep model of asthma. Am J Pathol 2005;166:935-944.
26. O'Byrne PM, Dolovich J, Hargreave FE. State of art: late asthmatic responses. Am Rev Respir Dis 1987;136:740-751.
27. Wright CD, Havill AM, Middleton SC, Kashem MA, Lee PA, Dripps DJ, O'Riordan TG, Bevilacqua MP, Abraham WM. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J Pharmacol Exp Ther 1999; 289:1007-1014.
28. Clark JM, Abraham WM, Fishman CE, Forteza R, Ahmed A, Cortes A, Warne RL, Moore WR, Tanaka RD. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 1995;152:2076-2083.
29. Krishna MT, Chauhan A, Little L, Sampson K, Hawksworth R, Mant T, Djukanovic R, Lee T, Holgate S. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001;107:1039-1045.
30. Belkowski SM, Masucci J, Mahan A, Kervinen J, Olson M, de Garavilla L, D'Andrea MR. Cleaved SLPI, a novel biomarker of chymase activity. Biol Chem 2008;389:1219-1224.
31. 1-proteinase inhibitor and tissue kallikrein in controlling allergic ovine airway hyperresponsiveness. Am J Respir Crit Care Med 1996;154:36-42.
32. Ahmed T, Campo C, Abraham MK, Molinari JF, Abraham WM, Ashkin D, Syriste T, Andersson LO, Svahn CM. Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin. Am J Respir Crit Care Med 1997;155:1848-1855.
33. Rubinstein I, Nadel JA, Graf PD, Caughey GH. Mast cell chymase potentiates histamine-induced wheal formation in the skin of ragweed-allergic dogs. J Clin Invest 1990;86:555-559.
34. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699.
35. Matin R, Tam EK, Nadel JA, Caughey GH. Distribution of chymasecontaining mast cells in human bronchi. J Histochem Cytochem 1992;40:781-786.
36. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006;117:1277-1284.
37. Reilly CF, Tewkbury DA, Schechter NM, Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 1983;257:8619-8622.
38. Myou S, Fujimura M, Kurashima K, Tachibana H, Watanabe K, Hirose T. Type 1 angiotensin II receptor antagonism reduces antigen-induced airway reactions. Am J Respir Crit Care Med 2000;162:45-49.
39. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol 2008;294:L612-L631.
40. Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 2002;11:965-980.
41. Korkmaz B, Poutrain P, Hazouard E, de Monti M, Attucci S, Gauthier FL. Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor. Am J Respir Cell Mol Biol 2005;32:553-559.
42. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004;3:831-844.
43. Belvisi MG, Hele DJ, Birrell MA. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Targets 2004;8:265-285.
44. Andersson MK, Karlson U, Hellman L. The extended cleavage speci-ficity of the rodent β-chymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase. Mol Immunol 2008;45:766-775.
45. Andersson MK, Enoksson M,Gallwitz M,Hellman L. The extended substrate specificity of the human mast cell chymase reveals a serine protease with well-defined substrate recognition profile. Int Immunol 2009;21:95-104.
46. Collie DDS, MacAldowie CN, Pemberton AD, Woodall CJ, McLean N, Hodgson C, Kennedy MW, Miller HRP. Local lung responses following local lung challenge with recombinant lungworm antigen in systemically sensitized sheep. Clin Exp Allergy 2001;31:1636-1647.
47. Liberman H, Mariassy AT, Sorace D, Suster S, Abraham WM. Morphometric estimation of superoxide generation in allergeninduced airway hyperresponsiveness. Lab Invest 1995;72:348-354.
48. Mistry R, Snashall PD, Totty N, Guz A, Tetley TD. Purification and N-terminal amino acid sequence of sheep neutrophil cathepsin G and elastase. Arch Biochem Biophys 1999;368:7-13.
49. O'Riordan TG, Otero R, Mao Y, Lauredo I, Abraham WM. Elastase contributes to antigen-induced mucociliary dysfunction in ovine airways. Am J Respir Crit Care Med 1997;155:1522-1528.
50. Adkison AM, Raptis SZ, Kelley DG, Pham CTN. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002;109:363-371.
51. Raptis SZ, Shapiro SD, Simmons PM, Cheng AM, Pham CTN. Serine protease cathepsin G regulates adhesion-dependent neutrophil effector functions by modulating integrin clustering. Immunity 2005;22:679-691.
52. Liu W, Hickey ER. Protease inhibitors for the potential treatment of chronic obstructive pulmonary disease and asthma. Annu Rep Med Chem 2008;43:171-185.